 |
|
Smoking Cessation With Varenicline, a Selective  4 2 Nicotinic Receptor Partial Agonist
Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell Nides, PhD;
Cheryl Oncken, MD, MPH;
David Gonzales, PhD;
Stephen Rennard, MD;
Eric J. Watsky, MD;
Rich Anziano, MS;
Karen R. Reeves, MD; for the Varenicline Study Group
Arch Intern Med. 2006;166:1561-1568.
Background Currently available smoking cessation therapies have limited success rates. Varenicline tartrate is a novel, selective nicotinic receptor partial agonist developed specifically for smoking cessation. This study evaluated the efficacy, tolerability, and safety of 3 varenicline doses for smoking cessation. Bupropion hydrochloride was included as an active control.
Methods A phase 2, multicenter, randomized, double-blind, placebo-controlled study of healthy smokers (18-65 years old). Subjects were randomized to varenicline tartrate, 0.3 mg once daily (n = 128), 1.0 mg once daily (n = 128), or 1.0 mg twice daily (n = 127), for 6 weeks plus placebo for 1 week; to 150-mg sustained-release bupropion hydrochloride twice daily (n = 128) for 7 weeks; or to placebo (n = 127) for 7 weeks.
Results During the treatment phase, the continuous quit rates for any 4 weeks were significantly higher for varenicline tartrate, 1.0 mg twice daily (48.0%; P<.001) and 1.0 mg once daily (37.3%; P<.001), than for placebo (17.1%). The bupropion rate was 33.3% (P = .002 vs placebo). The carbon monoxide–confirmed continuous quit rates from week 4 to week 52 were significantly higher in the varenicline tartrate, 1.0 mg twice daily, group compared with the placebo group (14.4% vs 4.9%; P = .002). The bupropion rate was 6.3% (P = .60 vs placebo). Discontinuation owing to treatment-emergent adverse events was 15.9% for bupropion, 11.2% to 14.3% for varenicline, and 9.8% for placebo. No dose-related increases occurred in adverse events for varenicline.
Conclusions Varenicline tartrate demonstrated both short-term (1 mg twice daily and 1 mg once daily) and long-term efficacy (1 mg twice daily) vs placebo. Varenicline was well tolerated and may provide a novel therapy to aid smoking cessation.
Author Affiliations: Los Angeles Clinical Trials, Los Angeles, Calif (Dr Nides); Department of Medicine, University of Connecticut Health Center, Farmington (Dr Oncken); Smoking Cessation Center, Department of Medicine, Oregon Health & Science University, Portland (Dr Gonzales); Pulmonary Division, University of Nebraska Medical Center, Omaha (Dr Rennard); and Pfizer Global Research and Development, Pfizer Global Pharmaceuticals, Groton, Conn (Drs Watsky and Reeves and Mr Anziano).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
New Weapon to Curb Smoking: No More Excuses to Delay Treatment
Bankole A. Johnson
Arch Intern Med. 2006;166(15):1547-1550.
EXTRACT
| FULL TEXT
Cytisine for Smoking Cessation: A Literature Review and a Meta-analysis
Jean-François Etter
Arch Intern Med. 2006;166(15):1553-1559.
ABSTRACT
| FULL TEXT
Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation
Cheryl Oncken, David Gonzales, Mitchell Nides, Stephen Rennard, Eric Watsky, Clare B. Billing, Richard Anziano, Karen Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1571-1577.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Retrospective Poison Center Review of Varenicline-Exposed Patients
Kreshak et al.
The Annals of Pharmacotherapy 2009;43:1986-1991.
ABSTRACT
| FULL TEXT
Acute Hepatic Injury Associated with Varenicline in a Patient with Underlying Liver Disease
Franck and Sliter
The Annals of Pharmacotherapy 2009;43:1539-1543.
ABSTRACT
| FULL TEXT
Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT
Safety and Effectiveness of Varenicline in a Veteran Population with a High Prevalence of Mental Illness
Purvis et al.
The Annals of Pharmacotherapy 2009;43:862-867.
ABSTRACT
| FULL TEXT
Varenicline-Associated Acute Renal Failure
Bird and Vesta
The Annals of Pharmacotherapy 2008;42:1908-1911.
ABSTRACT
| FULL TEXT
Varenicline for Tobacco Dependence
Hays and Ebbert
NEJM 2008;359:2018-2024.
FULL TEXT
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
Pirmoradi et al.
Am J Health Syst Pharm 2008;65:1624-1626.
ABSTRACT
| FULL TEXT
Smoking: A Deadly Pleasant Habit--Is There a Way Out?
Richter
ANGIOLOGY 2008;59:49S-53S.
ABSTRACT
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg et al.
CMAJ 2008;179:135-144.
ABSTRACT
| FULL TEXT
{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT
| FULL TEXT
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Rabe et al.
Am. J. Respir. Crit. Care Med. 2007;176:532-555.
ABSTRACT
| FULL TEXT
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT
Varenicline is useful for smoking cessation
Cadden
Thorax 2007;62:161-161.
FULL TEXT
Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT
Another Arrow in the Quiver to Combat Smoking
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT
New Weapon to Curb Smoking: No More Excuses to Delay Treatment.
Johnson
Arch Intern Med 2006;166:1547-1550.
FULL TEXT
|
